HER2 Status of Gastric Carcinoma and Corresponding Lymph Node Metastasis

详细信息    查看全文

• 作者：Fabio Pagni (1) (2)
  Stefano Zannella (1) (2)
  Susanna Ronchi (1) (2)
  Cristina Garanzini (1) (2)
  Biagio Eugenio Leone (1) (2)
  
• 关键词：Gastric cancer ; Metastasis ; HER2 ; IHC ; HER2 status scoring system
• 刊名：Pathology & Oncology Research
• 出版年：2013
• 出版时间：January 2013
• 年：2013
• 卷：19
• 期：1
• 页码：103-109
• 全文大小：229KB
• 参考文献：1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase III, open-label, randomised controlled trial. Lancet 376:687-7 external" href="http://dx.doi.org/10.1016/S0140-6736(10)61121-X">CrossRef
  2. Hoffmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:797-05 external" href="http://dx.doi.org/10.1111/j.1365-2559.2008.03028.x">CrossRef
  3. Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, H?fler H, Kreipe HH (2010) HER2 diagnostics in gastric cancer: guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457:299-07 external" href="http://dx.doi.org/10.1007/s00428-010-0952-2">CrossRef
  4. Wolff AC, Hammond EH M, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for Human Epidermal Growth Factor Receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18-3
  5. Albarello L, Pecciarini L, Doglioni C (2011) HER2 Testing in gastric cancer. Adv Anat Pathol 18:53-9 external" href="http://dx.doi.org/10.1097/PAP.0b013e3182026d72">CrossRef
  6. Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, Gardini G, Nizzoli R, Leonardi F, Gasparro D, Camisa R, Cavalli S, Silini EM, Ardizzoni A (2011) Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 104:1372-376 external" href="http://dx.doi.org/10.1038/bjc.2011.121">CrossRef
  7. Nassar A, Cohen C, Agersborg SS, Zhou W, Lynch KA, Albitar M, Barker EA, Vanderbilt BL, Thompson J, Heyman ER, Lange H, Olson A, Siddiqui MT (2001) Trainable Immunohistochemical HER/ / neu Image Analysis. A multisite performance study using 260 breast tissue specimen. Arch Pathol Lab Med 135:896-02
  8. Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH, Bokemeyer C, Izbicki JR, Sauter G (2009) HER-2 amplification is highly homogeneous in gastric cancer. Hum Pathol 40:769-77 external" href="http://dx.doi.org/10.1016/j.humpath.2008.11.014">CrossRef
  
• 作者单位：Fabio Pagni (1) (2)
  Stefano Zannella (1) (2)
  Susanna Ronchi (1) (2)
  Cristina Garanzini (1) (2)
  Biagio Eugenio Leone (1) (2)
  
  1. Department of Pathology, Desio Hospital, Desio, Italy
  2. University Milano Bicocca, Milan, Italy
  
• ISSN：1532-2807

文摘

Our goal is to verify HER2 status variability between primary tumor and metastatic site. Our second intention is to identify the most reliable criteria for pathological HER2 status assessment in gastric cancer node metastases since, at present, there is not a validated standard. 3 independent pathologists evaluated HER2 immunohistochemical and gene status (for IHC 2+ cases) in 34 gastric carcinoma metastatic lymph nodes and in their corresponding primary tumors. For primary gastric cancers, we followed the current HER2 assessment guidelines and for nodal metastases, we applied two immunohistochemical scoring systems with different cut-offs. The immunohistochemical inter-pathologists mean agreement was 71.4?% (κ--.45); a final score for each case was defined after collegial revision. By applying the two immunohistochemical criteria, we found 2 discordant cases, which can imply different pathological management. Moreover, a significantly different HER2 status between lymph node metastasis and primary tumor was obtained in 4 cases (concordance ratio 87.5?%). None of the patients would have undergone a different therapeutic pathway despite the scoring method applied. On the other hand we also detected a subset of patients who could have their therapeutic management changed, according to the differences between HER2 status in lymph nodes metastases and primary tumor.